Statements (16)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Robert_Alexander
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:developedBy |
antibody therapeutics
|
| gptkbp:focusesOn |
allergic and inflammatory diseases
|
| gptkbp:foundedYear |
2012
|
| gptkbp:founder |
gptkb:Robert_Alexander
|
| gptkbp:headquartersLocation |
gptkb:Redwood_City,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Allakos
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
lirentelimab
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
ALLK
|
| gptkbp:website |
https://www.allakos.com/
|
| gptkbp:bfsParent |
gptkb:Alta_Partners
|
| gptkbp:bfsLayer |
7
|